This new drug is a non-opioid analgesic, the first of its kind, designed to treat moderate to severe acute pain in adults.

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

Am J Health Syst Pharm. 2007;64(11):1148-1152. Health care organizations around the nation have been working to reduce the use of meperidine as a first-line agent for pain management. Despite the ...

Richard Silverman highlights some of the research that led to the discovery of a novel analgesic drug, while Bob Rappaport discusses his role in the regulation of analgesic drug products.

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would ...

Background and Objective: Oxycodone is a semisynthetic opioid analgesic drug classed as a strong opioid. The controlled-release oxycodone tablet formulation (OCRT) was approved in China in 2004 ...

Hyderabad: A analgesic drug, whose use resulted in the death of a 17-year-old student and the hospitalisation of two others, is a restricted medicine under Schedule H1, said the Telangana Anti ...

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research ...